Research & Development: Page 24
-
Podcast
Woman of the Week: Janssen’s Najat Khan
Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.
By Taren Grom • June 8, 2022 -
Profile
After losing her daughter to a rare disease, Sharon King is looking to rewrite the playbook of drug development
The communications pro is lending her community-building, storytelling expertise to the Bespoke Gene Therapy Consortium.
By Alexandra Pecci • June 7, 2022 -
Trendline
Oncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Pharma giants take on Appalachian cancer rates in newest screening initiative
AstraZeneca and Bristol Myers Squibb are teaming up with the nonprofit Association of Community Cancer Centers to increase lung cancer screening in rural Appalachia for the long haul.
By Karissa Waddick • June 7, 2022 -
Q&A // First 90 Days
First 90 Days: Janssen Immunology’s David Jimenez
The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.
By Taren Grom • June 6, 2022 -
How to build a cancer pipeline: Big Pharma oncology heads on driving science forward
Executives leading the cancer departments at J&J, Merck and Takeda chime in on what it takes to construct a successful and sustainable oncology drug pipeline.
By Michael Gibney • June 6, 2022 -
Profile
Flagship's creative approach to finding the next big idea in biopharma
Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.
By Alexandra Pecci • June 1, 2022 -
Cell and gene therapy advances coming fast and furious
A peek into R&D at the Mass General Brigham network reveals up-and-coming treatments pushing the boundaries of what’s possible in medicine.
By Kelly Bilodeau • June 1, 2022 -
Q&A // First 90 Days
First 90 Days: Sosei Heptares’ Chris Cargill
The company’s new CEO is looking to drive growth through collaboration and transparency.
By Kim Ribbink • May 31, 2022 -
Podcast
Woman of the Week: Ferring Pharmaceutical's Araz Raoof
Growing up in Iraqi Kurdistan, Raoof says a 'lethal combination' of books and strong women paved her way into STEM.
By Taren Grom • May 25, 2022 -
Q&A // First 90 Days
First 90 Days: Syneos Health’s Michelle Keefe
The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.
By Taren Grom • May 23, 2022 -
Podcast
Woman of the Week: Sparrow Pharmaceuticals' Jamie MacPherson
The vice president of regulatory affairs and quality on embracing leadership challenges in drug development.
By Taren Grom • May 18, 2022 -
Profile
Jumping into pharma with big plans at a small company
SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.
By Alexandra Pecci • May 17, 2022 -
Q&A
BriOri BioTech sets the stage for the comeback of Vioxx
With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.
By Kelly Bilodeau • May 17, 2022 -
Q&A // Biotech Spotlight
Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach
Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.
By Michael Gibney • May 17, 2022 -
Are digital DCTs the answer for rare diseases?
How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.
By Kim Ribbink • May 16, 2022 -
After 40 years, researchers discover new frontiers in the fight against HIV
Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.
By Karissa Waddick • May 16, 2022 -
Profile
With the shine of amyloid fading, tau is a rising star in Alzheimer's
The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.
By Michael Gibney • May 11, 2022 -
In the hot pharma talent market, execs battle these recruitment misconceptions
One of the top recruiting firms in life sciences weighs in on how companies can attract the next wave of rising stars.
By Meagan Parrish • May 11, 2022 -
FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have
New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.
By Kelly Bilodeau • May 10, 2022 -
Where hope and uncertainty meet: A cutting-edge cancer developer's winding road
Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.
By Alexandra Pecci • May 9, 2022 -
Q&A // Biotech Spotlight
Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia
With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.
By Taren Grom • May 9, 2022 -
Ultra-sensitive tests bring biomarkers into the drug development forefront
An agreement between the biomarker assay maker Quanterix and pharma giant Eli Lilly could help discover new ways to treat Alzheimer's.
By Michael Gibney • May 5, 2022 -
Podcast
Woman of the Week: Amgen's Dr. Jane Parnes
As executive medical director, early development at Amgen, Dr. Jane Parnes has helped guide clinical research for upwards of 30 of the company’s investigational molecules, including the newly approved Tezspire for severe asthma — one of her career highlights.
By Taren Grom • May 4, 2022 -
Profile
Breaking new ground: Longhorn's trailblazing effort to develop a universal flu vaccine
After years of success with their diagnostic platform for COVID-19, tuberculosis and the flu, the family funded company is shifting priorities back to the vaccine market.
By Taren Grom , Karissa Waddick • May 4, 2022 -
Profile
From cancer survivor to clinical trial innovator
How Alicia Staley is using her insights as a three-time cancer survivor to drive clinical trial improvements at Medidata.
By Kelly Bilodeau • May 3, 2022